Interim Report 1st April - 30th June, 2009
(Thomson Reuters ONE) - Continued strong revenue growth and good progress of R&D projectsApril - June* Total revenues before license revenues increased by 31 percent to SEK 319.9 M (243.8).* Operating result (EBIT) was SEK -13.1 M (-98.0). Earnings for the period amounted to SEK 16.8 M (-96.6), which is equivalent to an earnings per share of SEK 0.33 (-2.12).* Cash flow from operations was SEK 45.1 (-75.6). Cash and cash equivalents and short-term investments as of June 30th amounted to SEK 341.2 M (635.6).* Transfer costs related to Kineretâ and Kepivanceâ have increased the product rights with SEK 39.1 M and will be amortized over 15 years.* On June 1st, the launch of ReFacto AFâ in Europe was started.* One of the two clinical phase II studies with KiobrinaTM, successfully completed patient recruitment and the proof of concept study with ExinaldaTM also completed the enrolment of patients.* A clinical phase II study is proceeding well at 23 clinics in Europe to study the safety and the therapeutic efficacy of Sym001 in ITP patients. Two dose cohorts have been treated, and the independent safety committee has recommended to continue to the next dose group.* Out-licensing and divestment of primary care projects continue. On June 22nd , Biovitrum signed a Transferring Agreement with iNovacia AB to continue development of two metabolic disease projects.* A new performance based, long term share program was initiated and 231,585 new series C shares will be issued.* Peter Sellei and Hans Glemstedt from Investor AB were elected new members of the Board, Håkan ÿström was re-elected Chairman of the Board and the rest of the 2008 Board members were re-elected except from Anders Hultin and Toni Weitzberg from Nordic Capital who had declined re-electionJanuary - June* Total revenues before license revenues increased by 52 percent to SEK 675.1 M (443.8). Earnings for the period amounted to SEK -6.9 M (-98.7), which is equivalent to an earnings per share of SEK -0.14 (-2.16).* Cash flow from operations was SEK -83.1 M (-98.5).Events after the period* Biovitrum has entered into an exclusive distribution and marketing agreement with Megapharm Ltd. allowing Kineret and Kepivance to be commercialized in Israel.* Biovitrum has selected The Bank of New York Mellon (NYSE: BK), as the depositary bank for its Level I American Depositary Receipt (ADR) program.CEO comments:"In 2009 we have successfully continued our transformation ofBiovitrum into an international pharmaceutical company, which isreflected both by a gratifying sales development for our marketedproducts, and a good progress of our R&D projects. At the same time,we further divested non-core projects, of which the agreement withiNovacia regarding two projects is a good example. We continuestrengthening the infrastructure needed for our key products andgoing forward, we intend to grow both organically and throughacquisitions", says CEO Martin Nicklasson.For further information, please contactMartin Nicklasson, CEOPhone: +46 8 697 2545Göran Arvidson, CFOCell phone: +46 8 697 23 27Erik Kinnman, EVP Investor RelationsCell phone: +46 73 422 15 40erik.kinnman(at)biovitrum.comAbout BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. The company has revenues of approximately SEK 1.2billion and around 400 employees. The company head office is locatedin Sweden and it is listed on the Stockholm OMX Nordic Exchange. Formore information please visit www.biovitrum.comBiovitrum AB (publ) may be required to disclose the informationprovided herein pursuant to the Swedish Securities Markets Act. Theinformation was provided for public release on July 23, 2009 at 08:30a.m. CET.http://hugin.info/134557/R/1330489/314535.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 23.07.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 3890
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Interim Report 1st April - 30th June, 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
